EMERYVILLE, Calif. - Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company with a ...
Hosted on MSN1mon
International study shows updated hepatitis B vaccine more effective for people with HIVThe study, reported Dec. 1 in JAMA, showed that hepatitis B vaccine with a cytosine phosphoguanine adjuvant, known as HepB-CpG, (trade name Heplisav-B) induced protective levels of antibodies in ...
The company’s Heplisav-B vaccine, which is the only two-dose adult Hepatitis B vaccine, reported a significant year-over-year sales increase, reaching the upper end of the guidance for 2024.
"We are excited to announce that HEPLISAV-B has achieved record annual revenue in 2024, reflecting 26% growth year-over-year, and positioning us at the upper tier of our updated guidance range.
An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...
An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback